Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
GlucoTrack Inc (GCTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: GCTK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.28% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.72M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.19 | 52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 |
52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3442.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -161.01% | Return on Equity (TTM) -694.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5064418 | Price to Sales(TTM) - |
Enterprise Value -5064418 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.01 | Shares Outstanding 567456 | Shares Floating 428235 |
Shares Outstanding 567456 | Shares Floating 428235 | ||
Percent Insiders 8.84 | Percent Institutions 1.27 |
Upturn AI SWOT
GlucoTrack Inc
Company Overview
History and Background
GlucoTrack Inc. (OTC: GTRK) was founded in 2009 with the initial aim of developing a non-invasive glucose monitoring system. Over the years, the company has pivoted and focused on the development and commercialization of diagnostic devices for infectious diseases. A significant milestone was the acquisition of GenePOC in 2021, which brought a molecular diagnostic platform to its portfolio.
Core Business Areas
- Molecular Diagnostics: Development and commercialization of rapid, point-of-care molecular diagnostic solutions for infectious diseases, particularly respiratory pathogens.
- Diagnostic Platforms: Focus on providing accessible and easy-to-use diagnostic devices that can be deployed in various healthcare settings.
Leadership and Structure
Information regarding GlucoTrack Inc.'s current leadership team and specific organizational structure is not readily available in public domain. As an OTC traded company, detailed corporate governance and executive team disclosures may be limited compared to major exchange-listed companies.
Top Products and Market Share
Key Offerings
- GenePOC Devices: Offers a portfolio of molecular diagnostic instruments, including the GenePOC Dx platform, designed for rapid detection of various pathogens. Competitors include Luminex Corporation (now part of DiaSorin), Cepheid (Danaher), and Abbott Laboratories in the broader molecular diagnostics space.
Market Dynamics
Industry Overview
The molecular diagnostics market, especially for infectious diseases, is a rapidly growing sector driven by the increasing prevalence of infectious diseases, demand for rapid and accurate diagnostic tools, and advancements in technology. The COVID-19 pandemic significantly accelerated this market's growth and highlighted the importance of point-of-care testing.
Positioning
GlucoTrack Inc., through its GenePOC acquisition, is positioned in the point-of-care molecular diagnostics segment, aiming to provide rapid and reliable testing solutions. Its competitive advantage lies in its technology's ability to deliver results quickly in decentralized settings. However, it faces intense competition from larger, established players.
Total Addressable Market (TAM)
The global molecular diagnostics market is substantial and growing, estimated to be in the tens of billions of dollars annually and projected to continue expanding. GlucoTrack Inc. is targeting a niche within this TAM focused on rapid, point-of-care infectious disease testing. Its current market share is relatively small compared to industry giants.
Upturn SWOT Analysis
Strengths
- Proprietary molecular diagnostic technology (GenePOC platform)
- Focus on rapid, point-of-care testing
- Potential for diverse infectious disease applications
Weaknesses
- Limited brand recognition and market penetration
- Reliance on a single primary technology platform
- Financial resources may be constrained compared to larger competitors
- History of pivoting business focus
Opportunities
- Increasing demand for decentralized diagnostic testing
- Emergence of new infectious diseases
- Partnerships with healthcare providers and distributors
- Expansion into new geographical markets
Threats
- Intense competition from established diagnostic companies
- Regulatory hurdles and approvals
- Rapid technological advancements by competitors
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Cepheid (Danaher) (NASDAQ: DHR)
- Luminex Corporation (NASDAQ: LMNX) (now DiaSorin)
- Abbott Laboratories (NYSE: ABT)
Competitive Landscape
GlucoTrack Inc. faces formidable competition from large, established players in the molecular diagnostics market. Its primary advantage lies in its specific focus on rapid point-of-care solutions, but it struggles with the scale, resources, and brand recognition of its competitors.
Major Acquisitions
GenePOC
- Year: 2021
- Acquisition Price (USD millions):
- Strategic Rationale: To gain access to a proprietary molecular diagnostic platform for rapid, point-of-care infectious disease testing.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth trajectory has been marked by strategic shifts and acquisitions, notably the GenePOC acquisition. Specific revenue and profit growth figures are not publicly detailed.
Future Projections: Specific future growth projections from analyst estimates are not readily available for GlucoTrack Inc.
Recent Initiatives: The primary recent initiative has been the integration and commercialization of the GenePOC molecular diagnostic platform following its acquisition.
Summary
GlucoTrack Inc., primarily through its GenePOC acquisition, operates in the competitive molecular diagnostics market with a focus on rapid point-of-care solutions. While its technology offers potential, the company faces significant challenges in market penetration and competing against larger, well-established entities. Strengthening its financial position and expanding its distribution network are crucial for future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases (historical)
- Industry analysis reports (general market data)
- Financial news outlets (general market trends)
- SEC filings (limited for OTC companies)
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. Specific financial data for GlucoTrack Inc. as an OTC company is limited. This information is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlucoTrack Inc
Exchange NASDAQ | Headquaters Rutherford, NJ, United States | ||
IPO Launch date 2013-04-25 | CEO, President & Director Mr. Paul V. Goode Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 11 | Website https://glucotrack.com |
Full time employees 11 | Website https://glucotrack.com | ||
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.